摘要
目的探讨e抗原阳性慢性乙肝患者接受恩替卡韦与阿德福韦酯联合治疗的临床效果。方法抽取58例e抗原阳性慢性乙肝患者随机分为对照组(阿德福韦酯)、观察组(恩替卡韦联合阿德福韦酯)各29例,测评治疗后3个月、6个月、12个月时两组患者ALT复常率、HBV-DNA阴性率、HBeAg转阴率。结果两组治疗3个月、6个月、12个月后ALT复常率比较,差异均无统计学意义(P>0.05);观察组在治疗3个月、6个月后HBV-DNA阴性率、HBeAg转阴率均明显高于对照组(P<0.05),12个月时两组比较差异不显著(P>0.05)。结论恩替卡韦与阿德福韦酯联合治疗e抗原阳性慢性乙肝患者不会提高ALT复常率,但可以改善HBV-DNA阴性率、HBeAg转阴率,值得推广应用。
Objective To investigate the clinical efficacy of entecavir combined with adefovir dipivoxil in the patients with e antigen-positive chronic hepatitis B. Methods 58 patients with e antigen-positive chronic hepatitis B were selected and randomly divided into the control group （adefovir dipivoxil） and the observation group （entecavir combined with adefovir dipivoxil）, with 29 cases in each group. The ALT recun＇ence rate, HBV-DNA negative rate and HBeAg negative conversion rate were measured in the two groups at 3 months, 6 months and 12 months after treatment. Results There was no statistically significant difference in the recurrence rate of ALT between the two groups at 3 months, 6 months and 12 months afler treatment （P〉0.05）; the HBV-DNA negative rate and HBeAg negative conversion rate in the observation group were significantly higher than those in the control group at 3 months and 6 months after treatment （P〈0.05）. There was no significant difference between the two groups at 12 months after treatment（P〉0.05）. Conclusion Entecavir combined with adefovir dipivoxil in the patients with e antigen-positive chronic hepatitis B does not improve ALT recurrence rate. However, it can improve the HBV-DNA negative rate and HBeAg negative conversion rate, which is worthy of promotion and application.
作者
莫金荣
MO Jinrong(Department of Infectious Diseases,Laibin People＇s Hospital in Guangxi Zhuang Autonomous Region,Laibin 546100,China)
出处
《中国现代医生》
2018年第28期12-14,共3页
China Modern Doctor
关键词
E抗原阳性
慢性乙肝
恩替卡韦
阿德福韦酯
e antigen-positive
Chronic hepatitis B
Entecavir
Adefovir dipivoxil
